💡 本文重點導覽
- Liver: the most metabolically active ectopic fat site
- Heart: epicardial fat and cardiac risk
- Muscle: intramyocellular lipid and insulin resistance
📋 本文重點摘要
Visceral fat doesn't just accumulate around the waist — it infiltrates the liver, surrounds the heart, compresses the kidneys, and deposits in muscle tissue. This organ-level fat accumulation drives metabolic dysfunction far beyond what BMI or scale weight captures.
Visceral fat doesn't just accumulate around the waist — it infiltrates the liver, surrounds the heart, compresses the ki…
Visceral fat doesn’t stay neatly in the abdominal cavity — it infiltrates organs and deposits in anatomical locations that compromise their function. Ectopic fat accumulation in the liver (hepatic steatosis), around the heart (epicardial fat), around the kidneys (perirenal fat), and within muscle tissue (intramyocellular lipid) creates a comprehensive metabolic disruption that body weight measurements completely miss.
Liver: the most metabolically active ectopic fat site
Hepatic fat accumulation (MASLD) affects over 30% of adults globally and is directly driven by visceral fat’s free fatty acid drain into the portal vein. Every additional 1% of liver fat is associated with measurable increases in systemic insulin resistance, independent of BMI or total body fat. Hepatic fat reduces liver’s ability to clear insulin from portal blood, allowing higher systemic insulin levels that further worsen peripheral insulin resistance.
Heart: epicardial fat and cardiac risk
Epicardial fat — the fat pad surrounding the heart within the pericardial sac — is metabolically active, secreting inflammatory cytokines and free fatty acids directly into the myocardium and coronary arteries. Epicardial fat volume correlates with coronary artery disease severity independently of BMI and abdominal fat, and is now measured by cardiac CT as an independent cardiovascular risk marker in high-risk individuals.
Muscle: intramyocellular lipid and insulin resistance
Fat stored within muscle fibers (intramyocellular lipid, IMCL) directly impairs muscle insulin sensitivity by activating PKC (protein kinase C) through diacylglycerol intermediates. High IMCL is a consistent finding in insulin-resistant individuals and can be present in lean-appearing people with low subcutaneous fat but high visceral and ectopic fat. CNFCD is a science-based dietary coaching method developed by Weikang. Hsien-Hung Shih (ResetWith) provides dietary consultation using CNFCD, targeting the dietary conditions that drive ectopic fat accumulation.
CNFCD provides dietary and lifestyle guidance only. It does not replace medical diagnosis or treatment. Please consult your physician if you have health concerns.
👉 Ready to address your metabolic health through diet? Feel free to reach out for an initial consultation.
— Hsien-Hung Shih | ResetWith Health Coach | cnfcd.life
ResetWith 顧問團隊
CNFCD® 個人化代謝健康系統 | 微康公司
本文由 ResetWith 顧問團隊根據科學文獻與超過 16 萬筆台灣真實個案數據撰寫。所有內容以 CNFCD® 方法論為基礎,供健康參考使用。
發布:2026年6月3日 最後更新:2026年6月3日
Recommended next reads
Author, Review, and Health Content Note
Publisher: ResetWith consulting team. Principal consultant: Pangpang / Sean Shih. Last updated: 2026-06-03.
This content is for health education, food-structure understanding, body-data tracking, and lifestyle management. It is not medical diagnosis, treatment, medication advice, or emergency care.
Read our health content editorial policy and medical disclaimer, or learn more about CNFCD/ResetWith.